Pulmatrix Stock Net Income
| PULM Stock | USD 2.27 0.01 0.44% |
Fundamental analysis of Pulmatrix allows traders to better anticipate movements in Pulmatrix's stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.6 M | -9 M | |
| Net Loss | -11 M | -11.5 M | |
| Net Loss | -17 M | -17.8 M | |
| Net Loss | (2.36) | (2.47) | |
| Net Income Per E B T | 0.81 | 0.72 |
Pulmatrix | Net Income | Build AI portfolio with Pulmatrix Stock |
Pulmatrix Company Net Income Analysis
Pulmatrix's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Pulmatrix Net Income | (9.56 M) |
Most of Pulmatrix's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pulmatrix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pulmatrix Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pulmatrix is extremely important. It helps to project a fair market value of Pulmatrix Stock properly, considering its historical fundamentals such as Net Income. Since Pulmatrix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pulmatrix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pulmatrix's interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pulmatrix Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pulmatrix reported net income of (9.56 Million). This is 102.8% lower than that of the Pharmaceuticals sector and 113.65% lower than that of the Health Care industry. The net income for all United States stocks is 101.67% higher than that of the company.
Pulmatrix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pulmatrix's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pulmatrix could also be used in its relative valuation, which is a method of valuing Pulmatrix by comparing valuation metrics of similar companies.Pulmatrix is currently under evaluation in net income category among its peers.
Pulmatrix Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pulmatrix from analyzing Pulmatrix's financial statements. These drivers represent accounts that assess Pulmatrix's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pulmatrix's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 20.5M | 13.4M | 6.8M | 25.5M | 29.3M | 22.1M | |
| Enterprise Value | (31.1M) | (21.4M) | (3.6M) | 16.0M | 14.4M | 15.1M |
Pulmatrix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pulmatrix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pulmatrix's managers, analysts, and investors.Environmental | Governance | Social |
Pulmatrix Institutional Holders
Institutional Holdings refers to the ownership stake in Pulmatrix that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pulmatrix's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pulmatrix's value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 110.8 K | Jones Financial Companies Lllp | 2025-06-30 | 0.0 | Sbi Securities Co Ltd | 2025-06-30 | 60.6 K | Blackrock Inc | 2025-06-30 | 55.3 K | Vanguard Group Inc | 2025-06-30 | 47 K | Geode Capital Management, Llc | 2025-06-30 | 41.1 K | State Street Corp | 2025-06-30 | 13.9 K | Ubs Group Ag | 2025-06-30 | 5.5 K | Tower Research Capital Llc | 2025-06-30 | 408 | Citigroup Inc | 2025-06-30 | 90.0 | Bank Of America Corp | 2025-06-30 | 36.0 |
Pulmatrix Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | (1.27 M) | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Insiders | 0.66 % | ||||
| Shares Owned By Institutions | 9.46 % | ||||
| Number Of Shares Shorted | 4.3 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 1.74 X | ||||
| Price To Sales | 2,764 X | ||||
| Revenue | 7.81 M | ||||
| Gross Profit | (7.16 M) | ||||
| EBITDA | (7.04 M) | ||||
| Net Income | (9.56 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 996 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 1.30 X | ||||
| Cash Flow From Operations | (10.72 M) | ||||
| Short Ratio | 0.41 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.67 | ||||
| Market Capitalization | 8.29 M | ||||
| Total Asset | 9.94 M | ||||
| Retained Earnings | (297.16 M) | ||||
| Working Capital | 8.99 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
| Net Asset | 9.94 M |
About Pulmatrix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Pulmatrix Piotroski F Score and Pulmatrix Altman Z Score analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.